Zydus Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 12, 2025. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results.

Zydus Lifesciences held its 30th AGM on August 12, 2025, via video conferencing, where all 7 resolutions were passed with overwhelming majority (over 99% in favor). Key approvals include adoption of audited standalone and consolidated financial statements for FY ended March 31, 2025, declaration of a final dividend of ₹11 per share (1,100%) on a face value of ₹1, and re-appointment of Dr. Sharvil P. Patel as director. Shareholders also approved the re-appointment of Mr. Ganesh N. Nayak as a director for another 5-year term (July 12, 2025 to July 11, 2030) at a remuneration of ₹36 million per annum. Other approvals include ratification of cost auditors' remuneration of ₹0.85 million and appointment of SPANJ & Associates as Secretarial Auditor for 5 years (FY 2025-26 to 2029-30). Quorum was strong with 74.97% of paid-up equity share capital represented through remote e-voting and e-voting during the AGM.